Helius Med Technolog (HSDT) 0.7440 $HSDT U.S. Army and

New Post Public Reply Private Reply Replies (0) Message Board

Sep 12, 2015 at 10:23 AM

Helius Med Technolog (HSDT) 0.7440 $HSDT

U.S. Army and Helius Medical Technologies Announce Launch of Phase 3 Traumatic Brain Injury Clinical Trial
Business Wire - Tue Aug 11, 9:15AM CDT
Helius Medical Technologies (CSE: HSM) (OTCQB: HSDT) ("Helius", or the "Company"

and the U.S. Army Medical Research and Materiel Command ("USAMRMC"

announce the launch of a Phase 3 clinical trial to investigate the safety and effectiveness of the Portable Neuromodulation Stimulator ("PoNS(TM)"

4.0 device, a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury ("mTBI"

. The trial is intended to serve as the basis for seeking Canadian and U.S. marketing approvals of the PoNS(TM). The PoNS(TM) is an investigational medical device that is designed to induce neuromodulation by stimulating the cranial nerves found in the tongue.

Helius Medical Technologies Issues Corporate Update
TheNewswire.ca - Fri Aug 07, 8:15AM CDT
(via Thenewswire.ca)

Helius Medical Technologies Announces Closing of Cad $330,738 Non-Brokered Private Placement
TheNewswire.ca - Fri Jul 17, 4:31PM CDT
(via Thenewswire.ca)

Helius Medical Technologies Inventors Granted US Patent No. 9,072,889
Business Wire - Wed Jul 15, 10:04AM CDT
Helius Medical Technologies, Inc. (CSE:HSM)(OTCQB:HSDT) ("Helius", or the "Company"

announced today that the US Patent and Trademark Office ("USPTO"

issued the Company its first patent related to the design of the new Portable Neuromodulation Stimulation ("PoNS(TM)"

4.0 device. The PoNS(TM) is currently being studied in the United States for the treatment of chronic balance symptoms caused by mild-moderate Traumatic Brain Injury ("TBI"

and in Canada for chronic balance and gait symptoms caused by Multiple Sclerosis.

Helius Medical Technologies Inventors' Granted Us Patent No. 9,072,889, a Systems for Providing Non-Invasive Neurorehabilitation of a Patienta
TheNewswire.ca - Wed Jul 15, 8:15AM CDT
(via Thenewswire.ca)

U.S. Army and Helius Medical Technologies Execute Sole Source Contract for the PoNS(TM) Device Testing and Development
Business Wire - Tue Jul 07, 9:15AM CDT
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius" or the "Company"

announced that NeuroHabilitation Corporation ("NHC"

, a division of Helius, successfully executed a sole source cost sharing contract with the U.S. Army Medical Research and Materiel Command (USAMRMC). The contract will support Helius' registrational trial investigating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS(TM)), a non-invasive brain stimulation device that is being developed for the treatment of balance disorder in patients with mild-to-moderate Traumatic Brain Injury (mTBI).

Helius Medical Technologies Announces Closing of CAD $875,558 Non-Brokered Private Placement
TheNewswire.ca - Fri Jun 26, 5:30PM CDT
(via Thenewswire.ca)

Helius Medical Technologies Announces Clinical Device Readiness for PoNS(TM) 4.0
Business Wire - Thu Jun 25, 11:21AM CDT
Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ("Helius"

is pleased to announce that it has successfully released the first clinical version of the Portable Neuromodulation Stimulator (PoNS(TM)) 4.0 device. The PoNS 4.0 device is manufactured by Ximedica LLC and will be used in Helius' registrational clinical trial, to investigate its safety and effectiveness for the treatment of balance disorder caused by traumatic brain injury.

Helius Medical Technologies Announces Clinical Device Readiness for PoNS (tm) 4.0
TheNewswire.ca - Thu Jun 25, 8:19AM CDT
(via Thenewswire.ca)

Helius Medical Technologies Amends and Re-files Historical Financial Statements and Material Change Report
ACCESSWIRE - Thu Jun 04, 7:12PM CDT
NEWTOWN, PA / ACCESSWIRE / June 4, 2015 / Helius Medical Technologies, Inc. (CSE: HSM) (OTCQB: HSDT) ("HMT", or the "Company"

- As a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.

Helius Medical Technologies Achieves Full Enrollment in Canadian MS Feasibility Study
Business Wire - Wed May 20, 9:15AM CDT
Helius Medical Technologies ("Helius", "HMT", or the "Company"

announced that it has achieved full enrollment for its Multiple Sclerosis pilot clinical trial at the Montreal Neurological Institute. The trial, "Examining the efficacy of non-invasive neuromodulation in reducing symptoms of Multiple Sclerosis," launched in February 2015, is a 14-subject, blinded feasibility study investigating Helius' Portable Neuromodulation Stimulator (PoNS(TM)) and physiotherapy protocol on the rehabilitation of balance and gait symptoms in subjects with Multiple Sclerosis.

Helius Medical Technologies Announces Closing of Cad $2,208,110 Non-Brokered Private Placement
ACCESSWIRE - Thu Apr 30, 5:07PM CDT
NEWTOWN, PA / ACCESSWIRE / April 30, 2015 / Helius Medical Technologies, Inc. (CSE: HSM; OTCQB: HSDT) ("Helius", or the "Company"

is pleased to announce that it has closed a non-brokered private placement (the "Financing"

raising gross proceeds of CAD $2,208,110 (approximately USD $1,825,937) by the issuance of 849,273 units (each a "Unit"

at a price of CAD $2.60 per Unit (USD $2.15 per Unit). Each Unit consists of one (1) common share and one half of one (1/2) common share purchase warrant (each a "Warrant"

. Each whole Warrant entitles the holder thereof to purchase one additional common share of the Company at a price of approximately CAD $3.62 per share (USD $3.00 per share) for a period of thirty-six (36) months from the closing date of the Financing.

Helius Medical Technologies Inventors' Granted US Patent No. 14/341,141
Business Wire - Tue Apr 14, 9:20AM CDT
Helius Medical Technologies, Inc. (CSE:HSM)(OTCQB:HSDT) ("Helius", or the "Company"

announced today that the US Patent and Trademark Office (USPTO) issued a third patent related to its Portable Neuromodulation Stimulation (PoNS(TM)) device and the associated therapeutic modality. U.S. Patent No. 14/341,141 "Non-Invasive Neuromodulation (NINM) for Rehabilitation of Brain Function", issued on April 10, 2015, is directed to a non-invasive neuromodulation therapy that uses intraoral cutaneous stimulation in conjunction with cognitive exercise.

Helius Medical Technologies to Start Its Registrational Clinical Trial
Business Wire - Mon Apr 13, 12:04PM CDT
Helius Medical Technologies, Inc. (CSE:HSM) (OTCQB:HSDT) ("Helius"

is pleased to announce that it recently met with the US Food and Drug Administration ("FDA" or the "Agency"

as part of the Agency's pre-submission (pre-sub) process regarding Helius's protocol for its double-blind, randomized, sham-controlled study of the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNS(TM)) 4.0 device for cranial nerve noninvasive neuromodulation (CN-NINM) training in subjects with a chronic balance deficit due to mild-to-moderate traumatic brain injury (TBI).

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Toys"R"Us Rolls Out 160 U.S. Stores, NYC Celebration

Rebuilding the Toy Empire After a rough few years, Toys"R"Us is clawing its way back into the hearts—and wallets—of American shoppers. With 160+ new standalone stores popping up like mushrooms after rain, these guys aren't just playing games. This is a strategic move to reestablish their presence in the retail landscape just before the holiday shopping frenzy kicks...

Greenworks Mower Snags Best Electric Award for 2026

Greenworks Strikes Again with Top Lawn Mower Honors Man, when I think about the evolution from noisy, gas-guzzling lawn mowers to sleek, battery-powered beasts, Greenworks is right there, leading the charge. Just the other day, Popular Mechanics singled out the Greenworks 80V 22-inch Cordless Lawn Mower, handing it the coveted title of Best Electric Lawn Mower for 2026....

Perennial Housing Group's Big Move into Affordable Housing

Perennial's Ambitious Entry into the Affordable Housing Scene They say the real estate game's all about location, but when you’re diving into affordable housing, it's about necessity too. Perennial Housing Group, under the helm of seasoned CEO Gregory B. Jones, is kicking things off with a hefty acquisition—31 affordable housing communities spread across the Southeast...

Fly-E Faces Revenue Drop Amid Retail Restructuring

Downturn Despite Strategic Restructuring Today, we're diving into Fly-E Group, Inc. (NASDAQ:FLYE) and the latest shakeup in their financials—spoiler alert, it's riding a downward slope. Quarter two of fiscal 2027 didn't exactly shine a light on profitability. Net revenues slid, dropping to $2.6 million this quarter, down from $3.9 million the previous year. Tack that up...

ACR Poker's $20M OSS: Stakes High on Sunday Action

ACR Poker Takes the Spotlight with a Mammoth Sunday Sunday, November 15 is about to be a slugfest over at ACR Poker, as players gear up for an intense day of card-shuffling and betting. We’re looking at flights for all four headlining events of the Online Super Series (OSS) right alongside day two of The Quattro and an eye-popping WSOP Paradise Mega Satellite blowing...

WAX Collect Unveils Modular Flex Insurance for Watches

WAX Collect Pioneers Customized Insurance with WAX Flex™ In a world where even a simple escapement can change the watch industry, WAX Collect is shaking things up with its WAX Flex™, rolling out a tailor-made insurance product specifically for watch collectors who refuse to settle for one-size-fits-all coverage. It's the first of its kind in modular approaches,...

Matthew Callstrom Named CEO: Mayo Clinic's Next Era

Leadership Change at Mayo Clinic: A Turning Point The Mayo Clinic, a titan in healthcare lands, is on the cusp of a major leadership switch-up. As the trustees hand the reins to Dr. Matthew R. Callstrom, they're banking on a rich blend of experience and visionary thinking to steer their ship. We're looking at what this change might spell for Mayo's storied mission. Who is...

TagMaster To Acquire Kapsch's RFID Ops in NA Market

A Strategic Move in the Transportation Sector Here's a fresh shake-up for the North American transportation sector: TagMaster, alongside its U.S. subsidiary Sensys Networks, is all set to acquire Kapsch TrafficCom's RFID-focused North American components business. This isn't just a minor shuffle—this deal could ripple through the industry, promising strategic uplifts...

Secrets to Selecting Fresh Seafood for Your Boil

Navigating the Waters of Seafood Quality When it comes to throwing together a proper Louisiana seafood boil, your whole evening could sink or swim based on seafood freshness. Jonathan Sumich, a grocery veteran from Oak Point Fresh Market, spills the beans on picking the cream of the crop. Plan it right, and you’re the hero of the feast. Ignore these tips, and you might...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...